NYSE:PFEPharmaceuticals
Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer?
Pfizer (PFE) is back in focus after the FDA accepted a Priority Review for its supplemental New Drug Application for TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer.
See our latest analysis for Pfizer.
Pfizer’s latest oncology update lands after a mixed stretch for the stock, with the share price at US$24.54, a 1-month share price return of 1.03% but a 90-day decline of 7.33%. The 1-year total shareholder return of 8.03% contrasts with weaker 3 and 5-year total...